Progressive Supranuclear Palsy – Pipeline Review, H2 2017

Table of ContentsList of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Progressive Supranuclear Palsy – Overview
Progressive Supranuclear Palsy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Progressive Supranuclear Palsy – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Progressive Supranuclear Palsy – Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc
AlzProtect SAS
Asceneuron SA
Biogen Inc
Cortice Biosciences Inc
Intellect Neurosciences Inc
K-Stemcell Co Ltd
Merck & Co Inc
Prana Biotechnology Ltd
TauRx Therapeutics Ltd
UCB SA
Progressive Supranuclear Palsy – Drug Profiles
ABBV-8E12 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-120290 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-2006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DC-TAB – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-016 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gosuranemab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8719 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Tau for Progressive Supranuclear Palsy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBT-434 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Spinal Cord Injury, Alzheimer’s Disease, Progressive Supranuclear Palsy and Cerebral Palsy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TauC-3 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolfenamic acid – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPI-287 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRx-0237 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Progressive Supranuclear Palsy – Dormant Projects
Progressive Supranuclear Palsy – Product Development Milestones
Featured News & Press Releases
Nov 03, 2017: Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies
May 04, 2017: AlzProtect : The American Food and Drug Administration (FDA) Has Granted AZP2006 the Orphan Drug Designation for the Treatment of Progressive Supranuclear Palsy (PSP)
Apr 04, 2017: Asceneuron Receives Approval for Phase I Study of Oral Tau Inhibitor
Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer’s Disease and Progressive Supranuclear Palsy
Oct 13, 2016: C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy
Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy
Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Powered by WPeMatico